Skip to content

Study on the application and mechanism of synchronous percutaneous electrical stimulation of zusanli by stimulating GABABR to inhibit transient lower esophageal sphincter relaxation

Study on the application and mechanism of synchronous percutaneous electrical stimulation of zusanli by stimulating GABABR to inhibit transient lower esophageal sphincter relaxation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033065
Enrollment
Unknown
Registered
2020-05-19
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux

Interventions

Sponsors

The Third Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The main inclusion criteria are adult patients aged 18-65 with typical symptoms such as heartburn or/and reflux lasting for >= 6 months, including: 1. The first-treated GERD patients had not taken any drugs before enrollment; 2. Patients with GERD who have effective PPI but need long-term maintenance; 3. Refractory GERD patients, i.e., those who take PPI drugs regularly for 8-12 weeks, are still suffering from symptoms twice a day.

Exclusion criteria

Exclusion criteria: 1. Patients with scleroderma, diabetes or autonomic dysfunction; 2. Those patients with Barrett's esophageal syndrome, esophageal intraepithelial neoplasia or esophageal cancer, esophageal polyp, esophageal varices or ulcers of any grade, previous history of esophageal or gastric surgery, esophageal hiatal hernia >= 3cm; 3. Patients with serious complications (such as gastrointestinal bleeding, cardiopulmonary disease, serious hepatorenal disease, hematopoietic system disease, etc.); 4. Patients with nasopharynx obstruction; 5. Pregnant women, lactating women or women with pregnancy intention; 6. Patients familiar with acupuncture, acupoint or meridian treatment; 7. Patients who use antidepressants, ß - receptor antagonists, calcium antagonists, nitroglycerin and other drugs that affect esophageal motility at the same time; 8. With claustrophobia and other mental diseases; 9. Patients with previous implantation of metal materials.

Design outcomes

Primary

MeasureTime frame
the level of GABA in Brain;TLESR frequency;Reflux disease questionnaire;SF-36 questionnaire;

Countries

china

Contacts

Public ContactZhang Mieqing

The Third Affiliated Hospital of Zhejiang Chinese Medical University

zhangmq5569@sina.com+86 13858055850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026